Energy News / Shareholders Foundation, Inc.

NASDAQ:GBT Shareholder Notice: Investigation of Global Blood Therapeutics, Inc. over Possible Violations of Securities Laws

Via: ReleaseWire

Updated 11:15 AM CDT, Wed, September 26,2018

An investigation for investors in Global Blood Therapeutics, Inc. (NASDAQ: GBT) shares over potential securities laws violations by Global Blood Therapeutics was announced.

San Diego, CA -- (SBWIRE) -- 09/26/2018 -- Global Blood Therapeutics, Inc. is under investigation over potential securities laws violations by Global Blood Therapeutics in connection with certain financial statements.

Investors who purchased shares of Global Blood Therapeutics, Inc. (NASDAQ: GBT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Global Blood Therapeutics, Inc. (NASDAQ: GBT) concerning whether a series of statements by Global Blood Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. OnSeptember 13, 2018, Stat published an article describing "important risks that investors might be glossing over" regarding Global Blood's FDA approval prospects for its new drug to treat sickle cell disease, voxelotor. The article cited the results of a recent Phase 3 clinical trial and stated "Global Blood lacks data demonstrating voxelotor reduces the frequency of crises," which is traditionally a necessary criterion for FDA approval of a sickle cell disease treatment. The article further stated that, "[i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients."

Those who purchased shares of Global Blood Therapeutics, Inc. (NASDAQ: GBT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqgbt-shareholder-notice-investigation-of-global-blood-therapeutics-inc-over-possible-violations-of-securities-laws-1053914.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com